Upsher-Smith Laboratories, Inc. (PRNewsFoto/Upsher-Smith Laboratories, Inc.)
MAPLE GROVE, Minn., April 21, 2014 /PRNewswire/ --Upsher-Smith Laboratories, Inc. (Upsher-Smith), will highlight new pooled phase 1 data from studies in healthy adults comparing the adverse event profile of USL255 (Qudexy XR) with immediate-release topiramate in a poster presentation at the 66th Annual Meeting of the American Academy of Neurology (AAN) being held April 26 to May 3 in Philadelphia. Upsher-Smith, a fully integrated pharmaceutical company committed to the development of new treatments for diseases of the central nervous system (CNS), will be sponsoring 13 poster presentations at the meeting.
Qudexy XR (topiramate) extended-release capsules, which received Food and Drug Administration approval on March 11, 2014, is a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic (PK) profile. Qudexy XR is indicated as initial monotherapy in patients 10 years of age and older with partial-onset seizures or primary generalized tonic-clonic seizures. It is also approved as adjunctive therapy in patients 2 years of age and older with partial-onset seizures, primary generalized tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome. All strengths of Qudexy XR may be swallowed whole or administered by carefully opening the capsule and sprinkling the entire contents on a spoonful of soft food. This makes it the only approved extended-release topiramate product for patients who experience challenges swallowing whole capsules or tablets.
"The data being presented at this year's AAN meeting demonstrates Upsher-Smith's ongoing commitment to address the unmet needs of people living with seizure disorders," said Dr. William Pullman, MB BS, BMedSc, PhD, FRACP, Chief Scientific Officer, Upsher-Smith. "In particular, we look forward to presenting pooled Phase 1 data that further describes Qudexy XR's improved tolerability profile with respect to overall and cognitive adverse events compared with immediate-release topiramate."
Following is a guide to Upsher-Smith-sponsored data that will be presented during the AAN annual meeting:
USL255 (Qudexy XR (topiramate) extended-release capsules)
USL261 (intranasal midazolam)
INDICATIONS
Qudexy XR (topiramate) extended-release capsules is a prescription medicine used:
IMPORTANT SAFETY INFORMATION
View original post here:
New Data From Upsher-Smith's Epilepsy Portfolio To Be Highlighted At The 66th Annual Meeting Of The American Academy ...